trending Market Intelligence /marketintelligence/en/news-insights/trending/JOy1_63EagAARP65jSpEdw2 content esgSubNav
In This List

Protalix BioTherapeutics hires adviser to help explore strategic alternatives

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Protalix BioTherapeutics hires adviser to help explore strategic alternatives

Protalix BioTherapeutics Inc. hired a financial adviser to help it explore alternatives and potential partnerships to maximize shareholder value.

Protalix President and CEO Dror Bashan said the Israel-based biotechnology company aims to improve its capital structure, pursue strategic partnerships and move its pipeline toward commercialization.

The company develops protein-based therapies using its proprietary ProCellEx technology.

Protalix is looking for potential partners for its pipeline candidates including OPRX-106 and alidornase alfa, as well as partnerships that will use other companies' medicines in combination with its ProCellEx platform.